2
Clinical Trials associated with Autologous genetically modified ADPA2M4CD8 cells (Adaptimmune)A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in Subjects With Recurrent Ovarian Cancers
This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.
A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers
This study will investigate the efficacy of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose esophageal or esophagogastric junction (EGJ) cancer expresses the MAGE-A4 protein.
100 Clinical Results associated with Autologous genetically modified ADPA2M4CD8 cells (Adaptimmune)
100 Translational Medicine associated with Autologous genetically modified ADPA2M4CD8 cells (Adaptimmune)
100 Patents (Medical) associated with Autologous genetically modified ADPA2M4CD8 cells (Adaptimmune)
100 Deals associated with Autologous genetically modified ADPA2M4CD8 cells (Adaptimmune)